

Exploring Practical Implementation of Economic Incentives for Antimicrobial Development in the U.S.

July 20, 2016

Participant List

Hala Audi

Head of the Review Team, U.K. Review on Antimicrobial Resistance

Luciana Borio

Acting Chief Scientist, U.S. Food and Drug Administration

Helen Boucher

Attending Physician; Director, Infectious Diseases Fellowship Program; Associate Professor, Tufts Medical Center

Sam Bozette

Vice President of Medical Affairs, bioMerieux

Jason Brown

Director, Office of Microeconomic Analysis, U.S. Department of the Treasury

Angela Caliendo

Professor of Medicine, Brown University

Sara Calvert

Senior Clinical Project Manager, Clinical Trials Transformation Initiative

Sara Cosgrove

Director, Antimicrobial Stewardship Program; Professor of Medicine and Epidemiology, Johns Hopkins School of Medicine

Patrick Courneya

Executive Vice President and Chief Medical Officer, Hospitals, Quality and Care Delivery Excellence, Kaiser Permanente

Ed Cox

Director, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Gregory Daniel

Deputy Director, Duke-Margolis Center for Health Policy

Dennis Dixon

Chief, Bacteriology and Mycology Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Barry Eisenstein

Distinguished Physician, Antimicrobials, Merck & Co.

Prabhavathi Fernandes

Founder, President and CEO, Cempra

Steven Gitterman

Deputy Director, Division of Microbiology, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Robert Guidos

Senior Advisor to the Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Patrick Holmes

Vice President, Strategy, Portfolio and Commercial Operations, Pfizer

Amanda Jezek

Vice President of Public Policy and Government Relations, Infectious Diseases Society of America

Kirk Kerr

Economist, Office of Program and Strategic Analysis, Officer of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Adam Kroetsch

Policy and Informatics Advisor, U.S. Food and Drug Administration

Joe Larsen

Acting Deputy Director, Biomedical Advanced Research Development Authority

Lisa Lavange

Director, Office of Biostatistics Organization, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Gabriela Lavezzari

Research Director, Duke-Margolis Center for Health Policy

Ramanan Laxminarayan

Director and Senior Fellow, Center for Disease Dynamics, Economics & Policy

Shari Ling

Deputy Chief Medical Officer, Centers for Medicare and Medicaid Services

Lynn Marks

Senior Clinical Advisor for Infectious Diseases, GlaxoSmithKline

Mark McClellan

Director, Duke-Margolis Center for Health Policy

Anthony McDonnell

Head of Economic Research, U.K. Review on Antimicrobial Resistance

Clive Meanwell

Chief Executive Officer, The Medicines Company

Chantal Morel

Research Officer and Scientific Adjunct, London School of Economics and University of Geneva

Sumathi Nambiar

Director, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Kevin Outtersen

Professor of Law, Boston University

Linda Park

Analyst, Division of Medical Policy Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Ed Pezalla

National Medical Director for Pharmaceutical Policy and Strategy, Aetna

Jingyuan Qian

Research Assistant, Duke-Margolis Center for Health Policy

Charlene Reed

Chief Executive Officer, Foundation to Combat Antimicrobial Resistance

John Rex

Senior VP and Chief Strategy Officer, Infection Business Unit, AstraZeneca

David Ridley

Dr. and Mrs. Frank A. Riddick Associate Professor of the Practice of Business and Economics, Faculty Director, Health Sector Management, Fuqua School of Business, Duke-Margolis Center for Health Policy

Leonard Sacks

Associate Director for Clinical Methodology, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jonas Santiago

Deputy Director, Division of Medical Policy Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Stephanie Sassman

Disease Area Director, Infectious Diseases, Genentech

Andreas Schick

Senior Economist, U.S. Food and Drug Administration

Monika Schneider

Research Associate, Duke-Margolis Center for Health Policy

Arjun Srinivasan

Associate Director, Healthcare Associated Infection Prevention Programs, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention

Edward Stenehjem

Medical Director of Antibiotic Stewardship, Intermountain Healthcare

Melissa Stundick

Head of Strategic Alliances, Spero Therapeutics

Eugene Sun

Chief Executive Officer, Melinta Therapeutics

Ursula Theuretzbacher

Principal, Centre for Anti-Infective Agents

Chase Thomas

Manager of Federal Affairs, The McManus Group; Director of Alliance Development, Antimicrobial Innovation Alliance

Rose Tiernan

Medical Officer, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Brent Wallace

Chief Medical Officer, Intermountain Healthcare

Blake Wise

Chief Operating Officer, Achaogen